This story was originally published on Healthcare Dive. To receive daily news and insights, subscribe to our free daily Healthcare Dive newsletter. Dive Brief: Cigna’s Express Scripts could be nearing a settlement with the Federal Trade Commission in the agency’s lawsuit accusing the largest pharmacy benefit managers in the U.S. of driving up insulin prices. The FTC has suspended proceedings against Cigna’s subsidiaries — including PBM Express Scripts, health services division Evernorth and group purc ...

Top executives from five of the nation's largest health insurers began testifying on Thursday to lawmakers in both the U.S. House of Representatives and Senate about the rising costs of Americans' hea... ...

We came across a bullish thesis on The Cigna Group on The Passive Income Portfolio’s Substack. In this article, we will summarize the bulls’ thesis on CI. The Cigna Group's share was trading at $272.21 as of January 19th. CI’s trailing and forward P/E were 12.05 and 8.94 respectively according to Yahoo Finance. Mizuho Raised Waystar Target to $50, Reaffirmed Outperform After Q3 Strength The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United Sta ...

We recently compiled a list of the 10 Best Investments During A Recession. The Cigna Group stands sixth on our list among the best investments. TheFly reported on January 9 that Mizuho analyst Ann Hynes maintained a Buy rating on CI and adjusted the price target to $325 from $307. The firm noted that its physician survey shows healthcare utilization growth is slowing sequentially, suggesting the trend may be peaking. Separately, on January 13, 2026, The Cigna Group officially announced that it will relea ...

The Cigna Group (NYSE:CI) is one of the cheap S&P 500 stocks to invest in now. On January 6, Bernstein raised the firm’s price target on Cigna to $307 from $294 and kept a Market Perform rating on the shares. This decision was made as Bernstein anticipated a sector-wide turnaround for government Managed Care Organizations starting in 2026, though the firm cautioned that the path to recovery may be bumpy. The firm views current prices as attractive entry points across the board. A day before this rating, ...

Financial Results Announcement - The Cigna Group will release its fourth quarter 2025 financial results on February 5, 2026, by 6:30 a.m. Eastern Time (ET) [1] - A conference call to discuss these results will take place at 8:30 a.m. ET on the same day, with participants encouraged to join by 8:15 a.m. ET [1] - The call can be accessed via domestic and international numbers, and a replay will be available from 12:30 p.m. ET on February 5 until 10:59 p.m. ET on February 19, 2026 [1] Investor Relations Information - A copy of the news release and financial supplement will be available on The Cigna Group's website in the Investor Relations section by 6:30 a.m. ET on February 5, 2026 [2] Company Overview - The Cigna Group is a global health company focused on improving health outcomes and maintaining approximately 180 million customer relationships worldwide [3] - The company operates under various brands, including Cigna Healthcare and Evernorth Health Services, and has a presence in over 30 markets [3]

Core Viewpoint - Hankook Tire has opened the Hankook Tire Clinic Powered by Evernorth at its Clarksville, Tennessee manufacturing plant, providing accessible and affordable healthcare services to employees and their families [1][8]. Group 1: Clinic Services and Operations - The clinic offers a wide range of services including routine preventive care, primary care, acute care for common illnesses and injuries, chronic condition management, and select occupational health services [4]. - Operating hours for the clinic are Monday through Friday from 9:00 a.m. to 6:00 p.m., allowing employees to access care conveniently [5]. - All full-time and part-time employees, along with eligible family members, can utilize the clinic regardless of their health insurance plan, with low or no out-of-pocket costs [5]. Group 2: Investment and Community Impact - The establishment of the clinic is viewed as a significant investment in the health and well-being of employees, aiming to create a culture of wellness within the workplace [6]. - The partnership with Evernorth Health Services aims to enhance health outcomes and improve the overall employee experience, contributing to the long-term vitality of the Clarksville community [7]. Group 3: Company Background - Hankook Tire America Corp. is a growing leader in the U.S. tire market, focusing on technology, manufacturing, and marketing to deliver high-quality products [9]. - The company is a subsidiary of Hankook Tire & Technology Co., Ltd., which is listed in the Forbes Global 2000 and headquartered in Seoul, Korea [9].

Core Viewpoint - A report from Hunterbrook Media claims that major U.S. health care companies, including CVS Health Corp., UnitedHealth Group, and Cigna Group, are allegedly using shell companies to conceal billions of dollars that should be utilized to reduce drug prices for patients [1]. Group 1: Allegations of Financial Manipulation - The report suggests that pharmacy benefit managers (PBMs) are supposed to negotiate discounts with drugmakers and pass those savings to customers, but large insurers have allegedly created secret subsidiaries known as Group Purchasing Organizations (GPOs) to circumvent this obligation [3]. - Instead of taking a cut of the rebates, parent companies have their GPOs collect substantial "fees" from drugmakers, while PBMs claim to pass through 100% of the rebates received, effectively hiding billions in fees from public disclosure [4]. Group 2: Investigation Findings - Hunterbrook's investigation revealed that GPO offices in locations such as Ireland, Switzerland, and Minnesota, despite generating tens of billions of dollars, were largely empty, indicating a lack of legitimate business activity [5]. - The report emphasizes that these GPOs, which are claimed to help lower costs, are actually mechanisms for the insurers to protect their profits by siphoning off drug discounts intended for patients [6].

Core Insights - Cigna Group is positioned for growth driven by new business and expanded client relationships in the Evernorth Health Services unit [1] - The company has a market capitalization of $74.6 billion and offers a range of services including pharmacy services, benefits management, and health insurance products [2] Financial Performance - The Zacks Consensus Estimate for Cigna's 2025 earnings is $29.63 per share, reflecting an 8.4% year-over-year increase [3] - The consensus estimate for 2025 revenues is $272.11 billion, indicating a 10.1% rise, supported by expanding pharmacy benefit services and improved specialty volumes [4] Shareholder Value - Cigna has a robust shareholder value program, having repurchased 8.2 million shares for $2.6 billion and paid $1.2 billion in dividends in the first nine months of 2025 [5] - The company generated free cash flow of $7.4 billion over the past four quarters [5] Valuation Metrics - Cigna trades at a forward P/E of 9.28X, significantly below its five-year median of 10.62X and the industry average of 15.84X, indicating potential undervaluation [6] Key Concerns - Cigna's return on assets is 5.01%, below the industry average of 5.65%, suggesting less efficient asset utilization [7] - The company's net debt to capital ratio stands at 35.68%, higher than the industry average of 24.04%, raising concerns about its debt levels [7] - A high Medical Care Ratio (MCR) is impacting Cigna's healthcare profits, although a strategic plan is expected to drive long-term growth [8]

Core Insights - Cigna Group (CI) is a major player in the insurance industry, with a market cap of $74.6 billion, offering a range of insurance products including life, accident, disability, supplemental, Medicare, and dental insurance [1] Financial Performance - Analysts anticipate that Cigna will report a profit of $7.90 per share for Q4 2025, reflecting a 19% increase from $6.64 per share in the same quarter last year [2] - For the full fiscal year, Cigna's EPS is expected to be $29.63, an 8.4% increase from $27.33 in fiscal 2024, with a further rise to $30.56 projected for fiscal 2026 [3] Stock Performance - Cigna's stock has underperformed compared to the S&P 500 Index, which gained 16.9% over the past 52 weeks, while Cigna's shares only increased by 1.7% during the same period [4] - The stock also lagged behind the Health Care Select Sector SPDR Fund, which returned 13% in the same timeframe [4] Market Concerns - Investor concerns regarding Cigna's pharmacy-benefit management (PBM) business model have contributed to its underperformance, particularly due to a planned shift to a no-rebate pricing model by 2027 and the repricing of major contracts worth $90 billion in annual revenue, raising fears of transition risk and margin compression [5] Recent Earnings Report - On October 30, Cigna's shares fell over 17% despite reporting Q3 results that included an adjusted EPS of $7.83, surpassing Wall Street's expectations of $7.70, and adjusted revenue of $69.6 billion, exceeding the forecast of $67.2 billion [6] - Cigna expects its full-year adjusted EPS to be $29.60 [6] Analyst Ratings - The consensus opinion among analysts is bullish, with a "Strong Buy" rating overall; out of 23 analysts, 17 recommend a "Strong Buy," 2 suggest a "Moderate Buy," 3 give a "Hold," and 1 recommends a "Strong Sell" [7] - The average analyst price target for Cigna is $326.05, indicating a potential upside of 16.8% from current levels [7]